Presence of HER-2/neu-specific T cell responses in DCIS patients who have IFN-γ Rα positive lesions may suggest that these patients are at risk of developing HER-2/neu negative breast cancer. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.